First Time Loading...

Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SSE:600332

Watchlist Manager
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd Logo
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd
SSE:600332
Watchlist
Price: 32.08 CNY 0.82% Market Closed
Updated: May 3, 2024
Financials Section:
Income Statement Balance Sheet Cash Flow Statement

Income Statement

75.5B
+2%
Revenue
Growth Rates:
1 Year
+7%
3 Years
+22%
5 Years
+79%
7 Years
+277%
10 Years
+329%
4.7B
-0.3%
Operating Income
Growth Rates:
1 Year
+2%
3 Years
+45%
5 Years
+38%
7 Years
+307%
10 Years
+407%
4.1B
-5%
Net Income
Growth Rates:
1 Year
+2%
3 Years
+39%
5 Years
+18%
7 Years
+169%
10 Years
+314%

Earnings Waterfall
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

Revenue
75.5B CNY
Cost of Revenue
-61.3B CNY
Gross Profit
14.2B CNY
Operating Expenses
-9.5B CNY
Operating Income
4.7B CNY
Other Expenses
-656m CNY
Net Income
4.1B CNY

Income Statement
Guangzhou Baiyunshan Pharmaceutical Holdings Co Ltd

Rotate your device to view
Income Statement
Currency: CNY
Dec-2013 Mar-2014 Jun-2014 Sep-2014 Dec-2014 Mar-2015 Jun-2015 Sep-2015 Dec-2015 Mar-2016 Jun-2016 Sep-2016 Dec-2016 Mar-2017 Jun-2017 Sep-2017 Dec-2017 Mar-2018 Jun-2018 Sep-2018 Dec-2018 Mar-2019 Jun-2019 Sep-2019 Dec-2019 Mar-2020 Jun-2020 Sep-2020 Dec-2020 Mar-2021 Jun-2021 Sep-2021 Dec-2021 Mar-2022 Jun-2022 Sep-2022 Dec-2022 Mar-2023 Jun-2023 Sep-2023 Dec-2023
Revenue
Revenue
17 607
N/A
18 129
+3%
17 374
-4%
17 857
+3%
18 800
+5%
18 858
+0%
19 259
+2%
19 235
0%
19 125
-1%
19 442
+2%
19 502
+0%
19 597
+0%
20 036
+2%
20 272
+1%
20 293
+0%
20 459
+1%
20 954
+2%
22 575
+8%
24 679
+9%
34 863
+41%
42 234
+21%
53 380
+26%
60 735
+14%
62 421
+3%
64 952
+4%
63 882
-2%
62 081
-3%
61 774
0%
61 674
0%
64 735
+5%
67 333
+4%
68 329
+1%
69 014
+1%
69 507
+1%
70 106
+1%
70 280
+0%
70 788
+1%
71 878
+2%
73 538
+2%
74 167
+1%
75 515
+2%
Gross Profit
Cost of Revenue
(11 816)
(12 192)
(11 750)
(11 901)
(12 214)
(12 337)
(12 497)
(12 466)
(12 218)
(12 360)
(12 479)
(12 613)
(13 425)
(13 768)
(13 852)
(13 862)
(13 068)
(14 332)
(16 386)
(25 492)
(32 225)
(41 754)
(48 293)
(49 397)
(52 093)
(52 065)
(50 898)
(50 935)
(51 257)
(53 791)
(55 674)
(56 458)
(55 793)
(56 240)
(56 993)
(57 331)
(57 516)
(58 699)
(59 953)
(60 377)
(61 331)
Gross Profit
5 791
N/A
5 936
+3%
5 623
-5%
5 955
+6%
6 585
+11%
6 520
-1%
6 761
+4%
6 769
+0%
6 907
+2%
7 083
+3%
7 024
-1%
6 984
-1%
6 610
-5%
6 504
-2%
6 441
-1%
6 597
+2%
7 887
+20%
8 243
+5%
8 293
+1%
9 370
+13%
10 009
+7%
11 626
+16%
12 441
+7%
13 023
+5%
12 859
-1%
11 814
-8%
11 181
-5%
10 837
-3%
10 416
-4%
10 943
+5%
11 658
+7%
11 870
+2%
13 221
+11%
13 267
+0%
13 112
-1%
12 949
-1%
13 272
+2%
13 179
-1%
13 585
+3%
13 790
+2%
14 185
+3%
Operating Income
Operating Expenses
(4 863)
(4 940)
(4 695)
(4 990)
(5 391)
(5 269)
(5 421)
(5 380)
(5 742)
(5 912)
(5 970)
(5 997)
(5 454)
(5 268)
(4 844)
(4 841)
(5 979)
(5 806)
(5 903)
(6 594)
(6 586)
(8 404)
(8 477)
(8 991)
(8 961)
(8 116)
(8 120)
(7 387)
(7 172)
(7 189)
(7 529)
(7 951)
(9 010)
(8 841)
(8 743)
(8 481)
(8 665)
(8 555)
(8 966)
(9 065)
(9 473)
Selling, General & Administrative
(4 506)
(4 584)
(4 340)
(4 631)
(5 028)
(5 209)
(5 352)
(5 321)
(5 341)
(5 872)
(5 945)
(5 968)
(5 032)
(5 288)
(4 887)
(4 893)
(5 624)
(5 908)
(5 831)
(6 390)
(6 872)
(7 670)
(8 110)
(8 589)
(8 361)
(7 984)
(7 810)
(7 134)
(6 330)
(6 858)
(6 978)
(7 303)
(7 903)
(8 184)
(8 364)
(8 106)
(7 891)
(8 287)
(8 427)
(8 666)
(8 357)
Research & Development
0
0
0
0
(279)
0
0
0
(314)
0
0
0
(330)
0
0
0
(373)
0
(242)
(392)
(558)
(756)
(619)
(656)
(543)
(539)
(569)
(516)
(577)
(664)
(729)
(814)
(837)
(927)
(930)
(934)
(778)
(760)
(779)
(735)
(738)
Depreciation & Amortization
0
0
0
0
(73)
0
0
0
(76)
0
0
0
(83)
0
0
0
(86)
0
0
0
(213)
0
0
0
(444)
0
0
0
(499)
0
0
0
(529)
0
0
0
(587)
0
0
0
(641)
Other Operating Expenses
(357)
(356)
(355)
(359)
(12)
(59)
(67)
(57)
(12)
(39)
(26)
(29)
(8)
19
44
53
103
102
170
189
1 058
23
252
253
387
406
258
264
233
333
177
168
259
270
551
560
591
492
240
335
263
Operating Income
930
N/A
999
+7%
930
-7%
966
+4%
1 195
+24%
1 252
+5%
1 342
+7%
1 390
+4%
1 164
-16%
1 171
+1%
1 053
-10%
988
-6%
1 157
+17%
1 237
+7%
1 599
+29%
1 757
+10%
1 907
+9%
2 438
+28%
2 390
-2%
2 777
+16%
3 423
+23%
3 223
-6%
3 965
+23%
4 032
+2%
3 898
-3%
3 699
-5%
3 062
-17%
3 452
+13%
3 245
-6%
3 755
+16%
4 129
+10%
3 920
-5%
4 211
+7%
4 426
+5%
4 369
-1%
4 468
+2%
4 607
+3%
4 625
+0%
4 619
0%
4 724
+2%
4 712
0%
Pre-Tax Income
Interest Income Expense
190
210
215
246
172
155
137
95
246
281
288
331
310
318
363
374
556
584
1 689
1 742
531
1 257
66
(36)
156
101
71
84
429
436
529
560
529
585
502
517
450
539
656
644
389
Non-Reccuring Items
0
0
0
0
(4)
0
0
0
0
0
0
0
0
0
0
0
(4)
0
0
(2)
(119)
0
0
0
(1)
1
4
6
(4)
3
0
(0)
43
1
1
(0)
12
1
1
1
21
Gain/Loss on Disposition of Assets
(4)
(5)
(4)
(3)
(9)
0
0
(8)
(1)
0
0
0
15
0
15
15
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
0
Total Other Income
112
117
118
114
113
108
95
95
219
225
383
451
463
466
310
260
34
24
24
156
184
170
189
93
76
73
43
10
70
66
5
(12)
(60)
(66)
(7)
(10)
(27)
(30)
(32)
(31)
(12)
Pre-Tax Income
1 229
N/A
1 321
+7%
1 259
-5%
1 323
+5%
1 467
+11%
1 515
+3%
1 574
+4%
1 570
0%
1 628
+4%
1 676
+3%
1 724
+3%
1 768
+3%
1 945
+10%
2 021
+4%
2 287
+13%
2 406
+5%
2 493
+4%
3 046
+22%
4 103
+35%
4 674
+14%
4 019
-14%
4 650
+16%
4 220
-9%
4 089
-3%
4 129
+1%
3 875
-6%
3 181
-18%
3 553
+12%
3 739
+5%
4 260
+14%
4 664
+9%
4 468
-4%
4 723
+6%
4 945
+5%
4 866
-2%
4 975
+2%
5 043
+1%
5 134
+2%
5 244
+2%
5 339
+2%
5 110
-4%
Net Income
Tax Provision
(222)
(254)
(278)
(312)
(257)
(263)
(268)
(248)
(283)
(279)
(308)
(310)
(386)
(382)
(399)
(414)
(374)
(505)
(517)
(576)
(485)
(578)
(668)
(685)
(687)
(640)
(533)
(659)
(647)
(724)
(808)
(701)
(754)
(789)
(798)
(830)
(790)
(804)
(818)
(841)
(851)
Income from Continuing Operations
1 007
1 068
982
1 011
1 211
1 252
1 305
1 320
1 345
1 396
1 416
1 459
1 559
1 637
1 886
1 990
2 119
2 542
3 587
4 099
3 534
4 072
3 552
3 404
3 441
3 235
2 649
2 896
3 092
3 538
3 856
3 767
3 969
4 156
4 068
4 145
4 253
4 331
4 426
4 497
4 259
Income to Minority Interest
(27)
(32)
(24)
(11)
(18)
(13)
(12)
(25)
(45)
(50)
(58)
(62)
(51)
(56)
(53)
(54)
(57)
(60)
(65)
(84)
(93)
(130)
(183)
(243)
(252)
(269)
(243)
(207)
(176)
(179)
(203)
(200)
(249)
(258)
(261)
(262)
(287)
(261)
(238)
(214)
(204)
Net Income (Common)
980
N/A
1 036
+6%
958
-8%
1 000
+4%
1 192
+19%
1 239
+4%
1 294
+4%
1 296
+0%
1 300
+0%
1 345
+3%
1 356
+1%
1 396
+3%
1 508
+8%
1 584
+5%
1 835
+16%
1 938
+6%
2 062
+6%
2 482
+20%
3 523
+42%
4 015
+14%
3 441
-14%
3 943
+15%
3 370
-15%
3 162
-6%
3 189
+1%
2 966
-7%
2 405
-19%
2 688
+12%
2 915
+8%
3 358
+15%
3 653
+9%
3 567
-2%
3 720
+4%
3 898
+5%
3 807
-2%
3 883
+2%
3 967
+2%
4 069
+3%
4 188
+3%
4 283
+2%
4 056
-5%
EPS (Diluted)
1.2
N/A
0.81
-33%
0.74
-9%
0.77
+4%
0.92
+19%
0.96
+4%
0.96
N/A
0.99
+3%
1.01
+2%
1.04
+3%
1.06
+2%
1.05
-1%
1.08
+3%
0.97
-10%
1.12
+15%
1.18
+5%
1.27
+8%
1.52
+20%
2.16
+42%
2.46
+14%
2.12
-14%
2.42
+14%
2.07
-14%
1.95
-6%
1.96
+1%
1.83
-7%
1.46
-20%
1.66
+14%
1.79
+8%
2.07
+16%
2.25
+9%
2.2
-2%
2.29
+4%
2.4
+5%
2.34
-3%
2.39
+2%
2.44
+2%
2.5
+2%
2.58
+3%
2.63
+2%
2.49
-5%

See Also

Summary
Intrinsic value, competitors valuation, and company profile.
DCF Valuation
Stock valuation using Discount Cash Flow valuation method.
Relative Valuation
Stock valuation using valuation multiples.
Wall Street Estimates
Price targets and financial estimates made by Wall st analysts.
Profitability Analysis
Detailed analysis of the company's profitability.
Solvency Analysis
Analysis of the financial position and solvency of the company.
Financials
Income Statement, Balance Sheet, Cash Flow Statement.
Discount Rate
Stock discount rate: cost of equity and WACC.
Summary
DCF Valuation
Relative Valuation
Wall Street Estimates
Profitability Analysis
Solvency Analysis
Financials
Discount Rate
Discover More
ALPHA SPREAD
Join more than 133,900+ value investors using Alpha Spread
Create a free account
or see our plans & pricing

Company

About Us Careers Pricing Affiliate Program Terms of Service Privacy Policy

Help

What is Intrinsic Value? Help Center Contact Us

Tools

Stock Screener Intrinsic Value Calculator DCF Value Calculator Discount Rate Calculator

Stocks

Most Undervalued Stocks High Profitability Stocks High Solvency Stocks Most Popular Stocks

© 2024 Alpha Spread Limited. All Rights Reserved.

www.alphaspread.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on www.alphaspread.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall Alpha Spread Limited be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on www.alphaspread.com, or relating to the use of, or inability to use, www.alphaspread.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.